LEXINGTON, MA, iVexSol, a technology-based lentiviral vector contract development and manufacturing organization, announced $23.8 million in Series A-3 funding.
New investors Bristol Myers Squibb, Charles River Laboratories, and Asahi Kasei Medical, a division of Asahi Kasei, join existing investors which include Casdin Capital and BioLife Solutions to close Series A financing at a total of more than $39 million.
iVexSol is a viral vector manufacturing company founded on a proprietary, next-generation, stable lentiviral vector production process that transforms the way these essential gene-delivery vehicles are made. Its technology will greatly reduce the complexity, cost, and development time of these critical reagents, thereby accelerating the development and enabling greater access to life-changing cell and gene therapies.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about